Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 18 | 2022 | 983 | 4.630 |
Why?
|
| Renin-Angiotensin System | 15 | 2021 | 173 | 4.110 |
Why?
|
| Pneumonia, Viral | 11 | 2020 | 98 | 3.130 |
Why?
|
| Coronavirus Infections | 11 | 2020 | 95 | 3.120 |
Why?
|
| Peptidyl-Dipeptidase A | 6 | 2020 | 129 | 2.090 |
Why?
|
| Premature Birth | 5 | 2022 | 73 | 2.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2021 | 133 | 1.960 |
Why?
|
| Fetal Growth Retardation | 3 | 2022 | 33 | 1.450 |
Why?
|
| Peptide Fragments | 6 | 2021 | 417 | 1.270 |
Why?
|
| Kidney | 5 | 2022 | 520 | 1.200 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 1159 | 1.180 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2019 | 89 | 1.120 |
Why?
|
| Adolescent | 16 | 2022 | 3521 | 1.100 |
Why?
|
| Humans | 47 | 2022 | 32284 | 1.050 |
Why?
|
| Infant, Premature | 4 | 2019 | 74 | 0.950 |
Why?
|
| Child | 11 | 2022 | 2446 | 0.940 |
Why?
|
| Angiotensin I | 5 | 2021 | 237 | 0.910 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 115 | 0.890 |
Why?
|
| Graft Rejection | 2 | 2017 | 235 | 0.880 |
Why?
|
| Pregnancy | 8 | 2022 | 963 | 0.870 |
Why?
|
| Blood Pressure | 6 | 2022 | 866 | 0.800 |
Why?
|
| Female | 25 | 2022 | 19954 | 0.770 |
Why?
|
| Infant, Very Low Birth Weight | 6 | 2019 | 43 | 0.730 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 4 | 0.730 |
Why?
|
| Male | 24 | 2022 | 19434 | 0.730 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 490 | 0.720 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 62 | 0.700 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 12 | 0.690 |
Why?
|
| Hypophosphatemia | 1 | 2021 | 6 | 0.680 |
Why?
|
| Disease Progression | 2 | 2020 | 590 | 0.670 |
Why?
|
| Infant, Newborn | 9 | 2022 | 674 | 0.670 |
Why?
|
| Purpura, Schoenlein-Henoch | 1 | 2019 | 2 | 0.600 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 172 | 0.600 |
Why?
|
| Continental Population Groups | 2 | 2019 | 228 | 0.590 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 293 | 0.580 |
Why?
|
| Food Supply | 1 | 2019 | 64 | 0.560 |
Why?
|
| Fetus | 1 | 2019 | 75 | 0.560 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 83 | 0.560 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 18 | 0.550 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 87 | 0.550 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 1485 | 0.540 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 144 | 0.540 |
Why?
|
| Health Status Disparities | 1 | 2019 | 128 | 0.530 |
Why?
|
| Child Behavior | 1 | 2017 | 25 | 0.530 |
Why?
|
| Complement C4b | 1 | 2017 | 2 | 0.530 |
Why?
|
| Nutritional Status | 1 | 2017 | 73 | 0.510 |
Why?
|
| Child, Preschool | 5 | 2022 | 1248 | 0.500 |
Why?
|
| Overweight | 1 | 2018 | 252 | 0.490 |
Why?
|
| Dietary Supplements | 1 | 2017 | 187 | 0.480 |
Why?
|
| Creatinine | 3 | 2022 | 191 | 0.480 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 200 | 0.480 |
Why?
|
| Hyperpigmentation | 1 | 2016 | 17 | 0.460 |
Why?
|
| Peritoneal Dialysis | 1 | 2016 | 22 | 0.460 |
Why?
|
| Erythema | 1 | 2016 | 25 | 0.460 |
Why?
|
| Hot Temperature | 1 | 2016 | 81 | 0.460 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2015 | 5 | 0.450 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 25 | 0.450 |
Why?
|
| Isoantibodies | 1 | 2015 | 11 | 0.450 |
Why?
|
| Transplants | 1 | 2015 | 22 | 0.450 |
Why?
|
| Donor Selection | 1 | 2015 | 28 | 0.440 |
Why?
|
| HLA Antigens | 1 | 2015 | 40 | 0.440 |
Why?
|
| Angiotensin II | 4 | 2021 | 241 | 0.420 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 364 | 0.410 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3612 | 0.400 |
Why?
|
| Pain | 1 | 2016 | 303 | 0.390 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2238 | 0.380 |
Why?
|
| Sex Factors | 3 | 2019 | 656 | 0.370 |
Why?
|
| Nephrology | 2 | 2022 | 33 | 0.350 |
Why?
|
| Electronic Health Records | 3 | 2022 | 179 | 0.350 |
Why?
|
| Risk Factors | 6 | 2021 | 3938 | 0.320 |
Why?
|
| Virus Internalization | 2 | 2020 | 7 | 0.320 |
Why?
|
| Obesity | 1 | 2017 | 1108 | 0.310 |
Why?
|
| Renin | 2 | 2021 | 107 | 0.280 |
Why?
|
| Case-Control Studies | 2 | 2022 | 858 | 0.280 |
Why?
|
| Renal Dialysis | 2 | 2018 | 274 | 0.230 |
Why?
|
| Body Mass Index | 2 | 2018 | 863 | 0.220 |
Why?
|
| Prospective Studies | 2 | 2022 | 2320 | 0.220 |
Why?
|
| Sodium | 2 | 2021 | 41 | 0.210 |
Why?
|
| Potassium | 2 | 2021 | 40 | 0.210 |
Why?
|
| Comorbidity | 3 | 2020 | 563 | 0.210 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 106 | 0.180 |
Why?
|
| Losartan | 1 | 2022 | 64 | 0.180 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2022 | 66 | 0.170 |
Why?
|
| Aldosterone | 1 | 2021 | 26 | 0.170 |
Why?
|
| Lung Injury | 1 | 2022 | 67 | 0.170 |
Why?
|
| PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2021 | 3 | 0.170 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 18 | 0.170 |
Why?
|
| Health Personnel | 1 | 2022 | 113 | 0.170 |
Why?
|
| Medical History Taking | 1 | 2020 | 39 | 0.160 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 10 | 0.160 |
Why?
|
| Receptors, Virus | 1 | 2020 | 12 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 151 | 0.160 |
Why?
|
| Data Collection | 1 | 2021 | 171 | 0.160 |
Why?
|
| Electrolytes | 1 | 2020 | 11 | 0.160 |
Why?
|
| Pediatrics | 1 | 2022 | 157 | 0.160 |
Why?
|
| Tunica Intima | 1 | 2020 | 76 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2020 | 1424 | 0.160 |
Why?
|
| Prognosis | 3 | 2020 | 1529 | 0.160 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 36 | 0.160 |
Why?
|
| Rats, Inbred Lew | 1 | 2020 | 123 | 0.150 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 31 | 0.150 |
Why?
|
| Vitamin D | 1 | 2021 | 186 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2021 | 554 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2020 | 81 | 0.150 |
Why?
|
| Saliva | 1 | 2019 | 41 | 0.150 |
Why?
|
| Linear Models | 2 | 2017 | 426 | 0.150 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 19 | 0.150 |
Why?
|
| Hydrocortisone | 1 | 2019 | 64 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 246 | 0.150 |
Why?
|
| Proteinuria | 1 | 2019 | 52 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 650 | 0.150 |
Why?
|
| Algorithms | 1 | 2022 | 537 | 0.150 |
Why?
|
| Family Characteristics | 1 | 2019 | 32 | 0.150 |
Why?
|
| Prenatal Care | 1 | 2019 | 54 | 0.140 |
Why?
|
| Hospitalization | 4 | 2022 | 476 | 0.140 |
Why?
|
| Physical Fitness | 1 | 2019 | 120 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3410 | 0.140 |
Why?
|
| Infant | 2 | 2022 | 1024 | 0.140 |
Why?
|
| Logistic Models | 2 | 2017 | 743 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2019 | 49 | 0.140 |
Why?
|
| Angiotensins | 1 | 2018 | 42 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 555 | 0.140 |
Why?
|
| Placenta | 1 | 2019 | 74 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 180 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2018 | 55 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 388 | 0.130 |
Why?
|
| Animals | 2 | 2020 | 8165 | 0.130 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2018 | 28 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 302 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 17 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2022 | 1840 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 880 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2018 | 197 | 0.120 |
Why?
|
| Fetal Organ Maturity | 1 | 2016 | 5 | 0.120 |
Why?
|
| United States | 3 | 2022 | 4079 | 0.120 |
Why?
|
| Biopsy | 1 | 2017 | 249 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 293 | 0.120 |
Why?
|
| Gestational Age | 3 | 2022 | 125 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2018 | 394 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 14 | 0.120 |
Why?
|
| Rats | 1 | 2020 | 1892 | 0.110 |
Why?
|
| Complement Pathway, Classical | 1 | 2015 | 2 | 0.110 |
Why?
|
| Complement C1q | 1 | 2015 | 3 | 0.110 |
Why?
|
| Young Adult | 1 | 2022 | 2652 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 760 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2019 | 716 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 442 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2015 | 184 | 0.110 |
Why?
|
| Exercise | 1 | 2019 | 605 | 0.110 |
Why?
|
| North Carolina | 1 | 2018 | 1299 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2015 | 185 | 0.100 |
Why?
|
| Graft Survival | 1 | 2015 | 292 | 0.100 |
Why?
|
| Adult | 2 | 2022 | 9263 | 0.090 |
Why?
|
| Brain | 1 | 2019 | 966 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 532 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2022 | 34 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 773 | 0.080 |
Why?
|
| Exercise Test | 2 | 2019 | 218 | 0.070 |
Why?
|
| Birth Weight | 2 | 2019 | 46 | 0.070 |
Why?
|
| Survival Rate | 2 | 2021 | 892 | 0.060 |
Why?
|
| Incidence | 2 | 2020 | 1244 | 0.060 |
Why?
|
| Privacy | 1 | 2022 | 9 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 33 | 0.040 |
Why?
|
| Documentation | 1 | 2022 | 39 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 93 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 478 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 47 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 138 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2021 | 11 | 0.040 |
Why?
|
| Chromatography, Agarose | 1 | 2021 | 5 | 0.040 |
Why?
|
| Radioimmunoassay | 1 | 2021 | 25 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 28 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 204 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 31 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 566 | 0.040 |
Why?
|
| Veterans | 1 | 2021 | 64 | 0.040 |
Why?
|
| China | 1 | 2020 | 56 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 14 | 0.040 |
Why?
|
| Chlorides | 1 | 2020 | 13 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 66 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 17 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 64 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 101 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 190 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 101 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 83 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 755 | 0.040 |
Why?
|
| Aged | 2 | 2022 | 10257 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 316 | 0.030 |
Why?
|
| Lung | 1 | 2020 | 264 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 2018 | 9 | 0.030 |
Why?
|
| Calcium | 1 | 2020 | 337 | 0.030 |
Why?
|
| Middle Aged | 2 | 2022 | 11843 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 394 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2017 | 32 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 960 | 0.030 |
Why?
|
| Uric Acid | 1 | 2017 | 26 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 851 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 368 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1179 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 226 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 455 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 258 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1076 | 0.030 |
Why?
|
| Body Composition | 1 | 2017 | 327 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 1335 | 0.020 |
Why?
|